Precision Biosciences Inc (DTIL) saw an uptrend of 3.85% in the recent trading with $4.05 being its most recent. The current price level -54.08% lower than the highest price of $8.82 marked by the stock while trading over the past 52-weeks, whereas it is 8.05% higher than the lowest price of $3.75 the company dropped to over past 52-weeks. The latest news story on DTIL appeared in (Business Wire) under the title “Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 3 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Precision Biosciences Inc Earnings – What Happened With DTIL
Coming around sales and income figures on DTIL Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Precision Biosciences Inc (DTIL) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 27.47% for net revenue.
DTIL – Precision Biosciences Inc Stock Earnings Estimates
The perspective of Precision Biosciences Inc (NASDAQ:DTIL),s current quarter earnings identifies that analysts are in consensus over the estimate of -2.94 for stock,s EPS in the current quarter. Precision Biosciences Inc (DTIL) last released financial results for the quarter that ended 12/31/2024, posting a surprise factor of 27.47% for net revenue. Company,s EPS for the last quarter was -2.14.
Precision Biosciences Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 24.07 million. DTIL does have institutional investors; and they hold 28.18% of the stock.
As on 2024-06-30, JANUS HENDERSON GROUP PLC was the top most holder in Precision Biosciences Inc (NASDAQ:DTIL) with an ownership of 0.63 million shares of the company or 9.0879 of the stake worth $6.18 million. The filing also reveals TANG CAPITAL MANAGEMENT LLC as the second largest holder in the company with a control over 8.9473 of the outstanding shares. Its stake is worth $6.07 million for having 0.62 million shares in hand.
PERCEPTIVE ADVISORS LLC also came holding a key position in the company during the recent quarter and it now holds 6.119 of the outstanding shares. With this there are now 66.0 institutions which have possession in DTIL,s shares.
Key Metrics for DTIL
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Precision Biosciences Inc has a debt to equity ratio of 1.75.
